Please assess the completion status of the following clinical trial:

Trial Title: Development of Ursodeoxycholic Acid 300 mg at Hospital Das Clinicas of the University of São Paulo School of Medicine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Primary biliary cholangitis (PBC) was diagnosed when at least two of the following three criteria: histologically proven early stage PBC; positive Anti-mitochondrial antibody (AMA) (titer \>1:40) and alkaline phosphatase \>1.5 times upper limit of normal at any time since diagnosis.~* Patients had to be on ursodeoxycholic acid for at least 6 months.~* Patients should be able to understand and ready to sign the informed consent form.~Exclusion Criteria:~* Patients not adherent to treatment with reference medicine.~* Known intolerance to the study drugs.~* Patients who withdrew their agreement.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- capsule (Type: EXPERIMENTAL): pharmaceutical form: capsule ursodeoxycholic acid 300 mg 13-15mg/kg day 3 months
- tablet (Type: EXPERIMENTAL): pharmaceutical form: tablet ursodeoxycholic acid 300 mg 13-15mg/kg day 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).